Literature DB >> 22411345

Breast cancer: HER2--a good addiction.

Lisa A Carey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22411345      PMCID： PMC6699174          DOI： 10.1038/nrclinonc.2012.36

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

3.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

4.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors:  José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gómez; Phuong Dinh; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horváth; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Kunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymyr Probachai; Lajos Pusztai; Michael Untch; Richard D Gelber; Martine Piccart-Gebhart
Journal:  Lancet       Date:  2012-01-17       Impact factor: 79.321

5.  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Authors:  Michael Untch; Sibylle Loibl; Joachim Bischoff; Holger Eidtmann; Manfred Kaufmann; Jens-Uwe Blohmer; Jörn Hilfrich; Dirk Strumberg; Peter A Fasching; Rolf Kreienberg; Hans Tesch; Claus Hanusch; Bernd Gerber; Mahdi Rezai; Christian Jackisch; Jens Huober; Thorsten Kühn; Valentina Nekljudova; Gunter von Minckwitz
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

6.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Authors:  Kimberly L Blackwell; Harold J Burstein; Anna Maria Storniolo; Hope Rugo; George Sledge; Maria Koehler; Catherine Ellis; Michelle Casey; Svetislava Vukelja; Joachim Bischoff; Jose Baselga; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Authors:  Gunter von Minckwitz; Andreas du Bois; Marcus Schmidt; Nicolai Maass; Tanja Cufer; Felix E de Jongh; Eduard Maartense; Christoph Zielinski; Manfred Kaufmann; Wolfgang Bauer; Klaus H Baumann; Michael R Clemens; Ralph Duerr; Christoph Uleer; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

Review 8.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy.

Authors:  Sreenath V Sharma; Jeffrey Settleman
Journal:  Genes Dev       Date:  2007-12-15       Impact factor: 11.361
  8 in total
  11 in total

Review 1.  Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.

Authors:  Ashley G Rivenbark; Siobhan M O'Connor; William B Coleman
Journal:  Am J Pathol       Date:  2013-08-27       Impact factor: 4.307

Review 2.  Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis.

Authors:  Shailendra Dwivedi; Purvi Purohit; Radhieka Misra; Malavika Lingeswaran; Jeewan Ram Vishnoi; Puneet Pareek; Sanjeev Misra; Praveen Sharma
Journal:  Indian J Clin Biochem       Date:  2019-01-08

Review 3.  ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.

Authors:  Nico Jacobi; Rita Seeboeck; Elisabeth Hofmann; Andreas Eger
Journal:  Cancers (Basel)       Date:  2017-04-12       Impact factor: 6.639

4.  Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.

Authors:  Lorenzo Castagnoli; Egidio Iorio; Matteo Dugo; Ada Koschorke; Simona Faraci; Rossella Canese; Patrizia Casalini; Patrizia Nanni; Claudio Vernieri; Massimo Di Nicola; Daniele Morelli; Elda Tagliabue; Serenella M Pupa
Journal:  J Cell Physiol       Date:  2018-08-21       Impact factor: 6.384

5.  CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse.

Authors:  Ghina Taouk; Ola Hussein; Moussa Zekak; Ali Abouelghar; Yasser Al-Sarraj; Essam M Abdelalim; Manale Karam
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

Review 6.  Spoken and Unspoken Matters Regarding the Use of Opioids in Cancer.

Authors:  Janna Baker Rogers; Gerald M Higa
Journal:  J Pain Res       Date:  2022-04-05       Impact factor: 3.133

7.  Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization.

Authors:  Jakob C Stüber; Christian P Richter; Junel Sotolongo Bellón; Martin Schwill; Iwo König; Benjamin Schuler; Jacob Piehler; Andreas Plückthun
Journal:  Commun Biol       Date:  2021-06-21

8.  CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response.

Authors:  Laura P Saucedo-Cuevas; Isabel Ruppen; Pilar Ximénez-Embún; Samuel Domingo; Javier Gayarre; Javier Muñoz; Jose M Silva; María J García; Javier Benítez
Journal:  Oncotarget       Date:  2014-04-30

Review 9.  Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer.

Authors:  Joelle Zambrano; Elizabeth S Yeh
Journal:  Breast Cancer (Auckl)       Date:  2016-03-13

10.  Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients.

Authors:  Ali Abouelghar; Reem Hasnah; Ghina Taouk; Mohamad Saad; Manale Karam
Journal:  Oncotarget       Date:  2018-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.